TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04746703

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Pancreatic MRI will be performed in severe-obese patients with a planned bariatric surgery, before and 6 months after bariatric surgery.
Study: NCT04386538

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low Starch Diet (LSD)
Description: 6-week balanced diet program, adapted to individual energetic needs, with significant reduction of high content starchy food, naturally present in plant cells, roots, tubers, seeds, beans, legumes, fruits, and highly present in most farinaceous grains, especially in potatoes, corn, rice, pasta, bread, cookies and cakes.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General healthy eating
Description: 6-week balanced healthy eating counseling program, according to the World Health Organization recommendations.
Study: NCT06248255

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pads
Description: Single arm design in which each participant act as its own control. Wet or Dry pads are applied to the participants forearms.
Study: NCT05015699

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HT Supreme
Description: HT Supreme ( R\&D by Sinomed, Tianjin, China)
Study: NCT05145348

Intervention type: BIOLOGICAL
Intervention: Immune response to Sars-CoV-2 vaccinations; including COVID-19 vaccin Moderna, Comirnaty (Pfizer) and Vaxzevria (AstraZeneca)
Description: The vaccination is not part of the study, but part of the national immunization programme of the Netherlands. Blood will be drawn at 4 time points: baseline (t=1, \<2 months prior to first vaccination); t=2: 21-28 days after first vaccination and prior to second vaccination; t=3: 28 (21-42) days after second vaccination; t=4: 12 months (+/- 1 month) after second vaccination. Mucosal Lining Fluid (MLF) samples will be collected at 28 days (3-6 weeks) (t=3) and 12 (+/- 1) months (t=4) after the second vaccination.

Intervention type: BIOLOGICAL
Intervention: Immune response to Sars-CoV-2 vaccinations; including COVID-19 vaccin Moderna, Comirnaty (Pfizer) and Vaxzevria (AstraZeneca)
Description: The vaccination is not part of the study, but part of the national immunization programme of the Netherlands. Blood will be drawn at 4 time points: baseline (t=1, \<2 months prior to first vaccination); t=2: 21-28 days after first vaccination and prior to second vaccination; t=3: 28 (21-42) days after second vaccination; t=4: 12 months (+/- 1 month) after second vaccination. Mucosal Lining Fluid (MLF) samples will be collected at 28 days (3-6 weeks) (t=3) and 12 (+/- 1) months (t=4) after the second vaccination.

Intervention type: BIOLOGICAL
Intervention: Immune response to Sars-CoV-2 vaccinations; including COVID-19 vaccin Moderna, Comirnaty (Pfizer) and Vaxzevria (AstraZeneca)
Description: The vaccination is not part of the study, but part of the national immunization programme of the Netherlands. Blood will be drawn at 4 time points: baseline (t=1, \<2 months prior to first vaccination); t=2: 21-28 days after first vaccination and prior to second vaccination; t=3: 28 (21-42) days after second vaccination; t=4: 12 months (+/- 1 month) after second vaccination. Mucosal Lining Fluid (MLF) samples will be collected at 28 days (3-6 weeks) (t=3) and 12 (+/- 1) months (t=4) after the second vaccination.

Intervention type: BIOLOGICAL
Intervention: Immune response to Sars-CoV-2 vaccinations; including COVID-19 vaccin Moderna, Comirnaty (Pfizer) and Vaxzevria (AstraZeneca)
Description: The vaccination is not part of the study, but part of the national immunization programme of the Netherlands. Blood will be drawn at 4 time points: baseline (t=1, \<2 months prior to first vaccination); t=2: 21-28 days after first vaccination and prior to second vaccination; t=3: 28 (21-42) days after second vaccination; t=4: 12 months (+/- 1 month) after second vaccination. Mucosal Lining Fluid (MLF) samples will be collected at 28 days (3-6 weeks) (t=3) and 12 (+/- 1) months (t=4) after the second vaccination.
Study: NCT04738149

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimatoprost
Description: Participants will be receiving 2 drops per 4cm2 twice a week for 12 weeks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Excimer laser
Description: Participants will be receiving excimer laser 2x a week for 12 weeks

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Excimer laser
Description: Participants will be receiving excimer laser 2x a week for 12 weeks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microneedling with a dermaroller
Description: Participants will have 4cm2 area pre-treated with dermaroller 2x per week for 12 weeks
Study: NCT04865744

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide 7 MG Oral Tablet
Description: Semaglutide 7 mg oral tablet taken after an overnight fast with up to 120 ml of water.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet is taken after an overnight fast with up to120 ml of water.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide 14 MG Oral Tablet
Description: Semaglutide 14 mg oral tablet taken after an overnight fast with up to 120 ml water.
Study: NCT05508477

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaksin Merah Putih - UA SARS-CoV-2 (Vero Cell Inactivated) 5 µg
Description: Vaksin Merah Putih - UA SARS-CoV-2 (Vero Cell Inactivated) contains purified S protein of SARS-CoV-2 - Dose: 5 µg, aluminium hydroxide gel, 10 mM L-Histidine buffer, 0.005%, Tween Polysorbate 80, and 0.9% Sodium chloride. Vaccine will be prepared in vial (1 ml per vial). One vial will be used for one injection only. The vial should be shaken well before injection.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CoronaVac Biofarma COVID-19 Vaccine
Description: Control vaccine in this study is existing CoronaVac-BioFarma inactivated COVID-19 vaccine which has been used widely in Indonesia
Study: NCT06107660

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Description: Patients will receive either liposomal bupivacaine as part of the ESPB .

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: This is the control group comparator as this is standard of care at the investigator's institution.
Study: NCT04752345

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacoinvasive strategy
Description: Pharmacoinvasive treatment \[full-dose fibrinolysis combined with rescue PCI (in case of failed fibrinolysis) or routine early PCI (3 to 24 hours, in case of successful fibrinolysis)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reduced-dose facilitated PCI strategy
Description: Reduced-dose facilitated PCI\[reduced-dose fibrinolysis,simultaneously transfer,immediate coronary angiography and andioplasty when arrived at PCI center(\<3 hours)\]
Study: NCT05740319

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FMT
Description: FMT refers to transplanting healthy donor-derived microbiota to participants via oral capsule or injection of fecal suspension via nasojejunal tube.
Study: NCT05471180

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: protective spray film
Description: Skincare will be maintained with 3M Cavilon ® Cleansing Solution and the use of 3M Cavilon ® Protective Spray Film.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: protective spray film
Description: Skincare will be maintained with 3M Cavilon ® Cleansing Solution and the use of 3M Cavilon ® Protective Spray Film.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: photobiomodulation therapy
Description: application in 8 points of the affected perineum region, these applications will occur 1 x a day every 24 hours for three days.
Study: NCT05825625

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab 1,200 mg by IV infusion Q3W.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiragolumab
Description: Tiragolumab by IV infusion Q3W.
Study: NCT06237556

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients in the control group will receive placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin 5 MG
Description: Three days before the operation patients will receive 5 mg of melatonin (Melatonin, Nature Made, Canada, and USA) one hour before assigned sleep time until the time of discharge from hospital.
Study: NCT05274360

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile evidence-based aphasia therapy
Description: Use of mobile application to practice language for 2 weeks with a recommendation of 2 sessions per day of 20 minutes. The Android application, which is a Unity-based 2D game, will be installed on the patient's own phone, and they will play individually with the support of a family member if needed. The patients are free to start and stop using the application at any time. The application is safe to use, and it consists of therapeutic training methods such as object-matching, word search, writing, and manual voice recordings.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional aphasia rehabilitation
Description: Control Group (conventional aphasia rehabilitation). No therapy as patients are in the chronic stage, where they do not receive healthcare rehabilitation training.
Study: NCT06267638

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine group
Description: Participants will receive intraoperative ketamine during total knee arthroplasty

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: Participants will receive intraoperative normal saline during total knee arthroplasty
Study: NCT06335355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab + SHR-8068 + Pemetrexed + Carboplatin
Description: Adebrelimab,1200mg; SHR-8068, 1.0 mg/kg; Pemetrexed, 500mg/m2; Carboplatin, AUC 5 mg/mL/min

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Camrelizumab + Pemetrexed + Carboplatin
Description: Camrelizumab,200mg;Pemetrexed, 500mg/m2; Carboplatin, AUC 5 mg/mL/min

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adebrelimab + Pemetrexed + Carboplatin
Description: Adebrelimab,1200mg; Pemetrexed, 500mg/m2; Carboplatin, AUC 5 mg/mL/min
Study: NCT06316440

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wear noise-cancelling earphones
Description: Intervention of wearing noise-canceling earphones after general anesthesia
Study: NCT04798209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-777991 (SAD)
Description: ACT-777991 administered as hard capsules for oral use.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-777991 (SAD)
Description: ACT-777991 administered as hard capsules for oral use.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-777991 (SAD)
Description: ACT-777991 administered as hard capsules for oral use.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-777991 (SAD)
Description: ACT-777991 administered as hard capsules for oral use.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-777991 (SAD)
Description: ACT-777991 administered as hard capsules for oral use.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-777991 (SAD)
Description: ACT-777991 administered as hard capsules for oral use.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-777991 (SAD)
Description: ACT-777991 administered as hard capsules for oral use.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-777991 (SAD)
Description: ACT-777991 administered as hard capsules for oral use.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-777991 (MAD)
Description: ACT-777991 administered as hard capsules for oral use, once daily.
Study: NCT06200506

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transabdominal radiofrecuency application
Description: A transabdominal radiofrequency application will be performed, with a suprapubic active plate and a passive plate at the sacral level.~Patient position: Supine position. Sessions:9 Duration: 20 minutes Total intervention: 3 weeks.~Frequency: 3 times a week sessions will be held three times a week for three weeks
Study: NCT04626947

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Bezlotoxumab
Description: Bezlotoxumab infusion
Study: NCT05774587

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: mHealth control group
Description: Cardiac rehab control group

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mHealth technology assisted exercise counselling (mHealth)
Description: Exercise and counselling through mHealth technology
Study: NCT04726345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fexofenadine Hcl 180Mg Tab
Description: Fexofenadine 180mg tablet to be taken orally once a day until stent removal.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet to be taken orally once a day until stent removal.
Study: NCT04935112

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitravatinib
Description: 100 mg sitravatinib on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitravatinib
Description: 100 mg sitravatinib on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitravatinib
Description: 100 mg sitravatinib on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitravatinib
Description: 100 mg sitravatinib on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole
Description: 40 mg QD on Day 1 to Day 7 of Period 2 in Group 1
Study: NCT06498232

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Video Based Exercises
Description: Warm-up and cool-down will consist of aerobic games (Step, Hula Hoop, Rhythm Parade Dance, Run) available in Nintendo Wii. Balance games will consist of Penguin Slide, Soccer Heading, Table Tilt, Balance Bubble, Ski Slalom, Ski Jump, Tilt City, and Snowboard Slalom. Among the sports games, Bowling, Boxing, Tennis, and Baseball will be included in the program. In all games, progress will be made by increasing the difficulty levels, and in balance games, the game will be made more difficult with an additional balance board and bosu.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stabilization and Strengthening Exercises
Description: Warm-up exercises will consist of active dynamic warm-up exercises. Stabilization and strengthening exercises; extremity movements will begin with teaching respiratory control in supine, prone, sitting, crawling, squat, and standing positions, and will be made more difficult with the addition of exercise tires and exercise balls. Balance exercises will start from static positions and move on to dynamic positions with the inclusion of different surfaces. In the cooling exercises, in addition to breathing exercises, stretching exercises will be performed for the trunk, upper and lower extremities.

Intervention type: OTHER
Group type: OTHER
Intervention: Waiting List-Spine protection principles training
Description: Participants will be placed on a waiting list. Following the initial evaluations, participants will be informed that they will be included in an exercise program at the end of 6 months. During this process, participants in the control group will be called by phone at the 6th, 12th, and 18th weeks to question their status and to remind them that they will start the exercise program after a while. It will be evaluated at the end of 6 months, and the end of the study, exercise training approaches in the intervention group will be applied to participants who wish to do so, with the same protocol and duration.
Study: NCT05215106

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Following preparation of durvalumab, the entire contents of the IV bag should be administered as an IV infusion over approximately 60 minutes (±5 minutes), using a 0.2μm in-line filter (or add-on filter).
Study: NCT04798209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-777991 (MAD)
Description: ACT-777991 administered as hard capsules for oral use, once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-777991 (MAD)
Description: ACT-777991 administered as hard capsules for oral use, once daily.
Study: NCT06200506

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intracavitary radiofrequency application
Description: An intracavitary vaginal radiofrequency application will be performed, with an active intracavitary head and with a fixed plate at the sacral level.~Patient position: Supine position. Sessions:9 Duration: 20 minutes Total intervention: 3 weeks. Frequency: 3 times a week sessions will be held three times a week for three weeks.
Study: NCT05605834

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 9.5% hydrogen peroxide bleaching (POLA DAY advanced tooth whitening system, SDI) using a tray with reservoir
Description: Patients will be randomly divided into two groups. Alginate impressions of maxillary dental arches of patients will be taken to obtain casts and produce the customized trays.~Reservoirs 1 mm thick will be created on the facial surfaces of anterior teeth, including the first premolars in the arches, applying a light-cured resin on the casts. The resin layer thickness will be standardized using a thickness gauge (1.5 mm thickness). Then, customized trays will be fabricated with 0.9-mm-thick vinyl acetate sheets using the thermoforming process. Trays will be precisely trimmed completely involving tooth surface (1 mm incisal or occlusal to gingival margin), and the adaptation will be verified on the casts. The trays will be placed over teeth to verify the adaptation in the patients' mouth.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 9.5% hydrogen peroxide bleaching (POLA DAY advanced tooth whitening system, SDI) using a tray without reservoir.
Description: Alginate impressions of maxillary dental arches of patients will be taken to obtain casts to produce the customized trays. Then, customized trays will be fabricated with no space for reservoir, with 0.9-mm-thick vinyl acetate sheets using the thermoforming process applying a light-cured resin on the casts. Trays will be precisely trimmed completely involving tooth surface (1 mm incisal or occlusal to gingival margin), and the adaptation will be verified on the casts. The trays will be placed over teeth to verify the adaptation in the participants' mouths.
Study: NCT06457529

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: conventional treatment with Prolotherapy
Description: Group A got prolotherapy along with conven¬tional treatment, which includes ultrasonic therapy for 10 minutes. The intensity will be 3MHz at 1.0 watts/cm2.~Prolotherapy is an injection treatment used to relieve pain. Your healthcare provider will inject a small amount of an irritant into your body. Dextrose (sugar) solution is the most commonly injected irritant. Proponents of prolotherapy claim it relieves pain by jumpstarting your body's natural healing abilities.

Intervention type: OTHER
Group type: OTHER
Intervention: Dry Needling and conventional treatment
Description: Group B Subjects in Group B will get Dry Needling along with conventional treatment, which includes ultrasonic therapy for 10 minutes. The intensity will be 3MHz at 1.0 watts/cm2.~Trigger-point dry needling is an invasive procedure where a fine needle or acupuncture needle is inserted into the skin and muscle
Study: NCT04181606

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esmolol infusion
Description: The Esmolol loading dose will be 0.5 mg/kg fat free mass/min administered over the first 3 minutes, followed by a maintenance dose of 0.25 mg/kg fat free mass/min for the remainder of the protocol (maximum of 60 minutes).
Study: NCT04798209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-777991 (MAD)
Description: ACT-777991 administered as hard capsules for oral use, once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-777991 (MAD)
Description: ACT-777991 administered as hard capsules for oral use, once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (SAD)
Description: ACT-777991 matching placebo administered as hard capsules for oral use.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (SAD)
Description: ACT-777991 matching placebo administered as hard capsules for oral use.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (SAD)
Description: ACT-777991 matching placebo administered as hard capsules for oral use.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (SAD)
Description: ACT-777991 matching placebo administered as hard capsules for oral use.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (SAD)
Description: ACT-777991 matching placebo administered as hard capsules for oral use.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (SAD)
Description: ACT-777991 matching placebo administered as hard capsules for oral use.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (SAD)
Description: ACT-777991 matching placebo administered as hard capsules for oral use.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (SAD)
Description: ACT-777991 matching placebo administered as hard capsules for oral use.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (MAD)
Description: Matching placebo administered as hard capsules for oral use, once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (MAD)
Description: Matching placebo administered as hard capsules for oral use, once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (MAD)
Description: Matching placebo administered as hard capsules for oral use, once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (MAD)
Description: Matching placebo administered as hard capsules for oral use, once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (MAD)
Description: Matching placebo administered as hard capsules for oral use, once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 14C-ACT-777991 microtracer (SAD - Absolute Bioavailability)
Description: Single dose of 14C-ACT-777991 microtracer, administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Microtracer matching placebo (SAD - Absolute Bioavailability)
Description: Single dose of 14C-ACT-777991 microtracer matching placebo, administered intravenously.